Last updated: August 26, 2026
Lorazepam is a mature, genericized benzodiazepine with limited conventional patent protection but meaningful formulation opportunities. The strongest commercial positions are alcohol-free oral liquids, low-propylene-glycol injectable products, orally disintegrating or buccal dosage forms, pediatric and geriatric presentations, and hospital-ready packaging. The main barriers are controlled-substance regulation, bioequivalence, dose uniformity, excipient tolerability, and the need to demonstrate a clinically credible advantage over low-cost tablets and established concentrates.
What dosage forms and excipients are used in lorazepam products?
Lorazepam is marketed primarily as immediate-release tablets, oral concentrate and injectable solution. The active ingredient has low water solubility, which drives the use of cosolvents in liquid and parenteral products.
| Dosage form |
Typical strength |
Commercial reference |
Representative excipient strategy |
| Immediate-release tablet |
0.5, 1, 2 mg |
Ativan and generics |
Lactose, microcrystalline cellulose, polacrilin potassium, magnesium stearate |
| Oral concentrate |
2 mg/mL |
Ativan Intensol and generics |
Polyethylene glycol, propylene glycol and alcohol-based cosolvent system |
| Injection |
2 or 4 mg/mL |
Ativan injection and generics |
Polyethylene glycol, propylene glycol and alcohol-based solvent system |
| Potential ODT or buccal product |
0.5-2 mg, proposed |
No dominant U.S. reference product |
Mannitol, crospovidone, low-substituted hydroxypropyl cellulose, taste-masking and mucoadhesive systems |
FDA labeling identifies lactose, microcrystalline cellulose, polacrilin potassium and magnesium stearate in representative lorazepam tablet products. Liquid and injectable products use solvent systems because lorazepam is not readily soluble in water. Product-specific inactive ingredients vary by manufacturer and strength.[1-3]
Tablet excipient strategy
The conventional tablet formulation is technically straightforward and has a low cost of goods. Lactose-based tablets are suitable for much of the market, but they leave room for differentiated products targeting patients with lactose intolerance, excipient sensitivities or swallowing difficulties.
Commercially relevant alternatives include:
- Mannitol-based tablets for a lower-lactose or lactose-free positioning.
- Microcrystalline cellulose and dibasic calcium phosphate systems for direct compression.
- Crospovidone or croscarmellose sodium for faster disintegration.
- Low-substituted hydroxypropyl cellulose for rapid tablet breakup without excessive swelling.
- Film coatings that reduce powdering, improve handling and support product identification.
- Unit-dose blister packaging for controlled-substance inventory management.
The most defensible tablet opportunity is not a simple excipient substitution. It is a formulation with a measurable benefit, such as faster disintegration, improved swallowability, reduced friability or a lower-risk excipient profile.
What excipient opportunities exist for lorazepam oral liquids?
The largest liquid-formulation opportunity is a reduced-cosolvent or cosolvent-free product. Existing lorazepam concentrates rely on polyethylene glycol, propylene glycol and alcohol. These solvents support drug solubilization but create tolerability and handling concerns, particularly in children, older adults, patients with hepatic or renal impairment, and patients receiving repeated doses.
Alcohol-free oral solution
An alcohol-free product could target:
- Pediatric use where alcohol exposure is commercially and clinically sensitive.
- Geriatric patients taking multiple sedating medicines.
- Long-term or repeated dosing in institutional settings.
- Patients with alcohol-use disorder.
- Pharmacies and hospitals seeking simpler excipient-risk reviews.
Potential technologies include cyclodextrin complexes, pH-controlled solubilization, surfactant systems, nanosized drug dispersions and co-solvent reduction. Each approach requires evaluation of taste, precipitation after dilution, microbial control, container compatibility and chemical stability.
Cyclodextrins may improve aqueous solubility, but the selected grade and exposure level affect regulatory acceptability. Sulfobutyl ether-beta-cyclodextrin is widely used in injectable products, while hydroxypropyl-beta-cyclodextrin is used in some oral systems. The commercial case depends on achieving a meaningful reduction in alcohol, propylene glycol or polyethylene glycol without creating a higher-cost formulation with no clinical advantage.
Ready-to-administer oral dosing
A calibrated oral syringe, unit-dose cup or premeasured sachet can create value even when the formulation is not novel. Lorazepam concentrate dosing errors are commercially relevant because the product is potent and commonly administered in small volumes.
A differentiated product could combine:
- A low-volume, high-concentration solution.
- A supplied oral syringe with dose markings.
- Tamper-evident unit-dose packaging.
- Child-resistant, senior-friendly packaging.
- A formulation that remains stable after limited dilution in approved vehicles.
The labeling must support the dosing device and specify compatibility, dilution limits and storage conditions. The device and formulation can be developed as a combination product if the delivery system is essential to intended use.
What formulations are protected by lorazepam patents?
Lorazepam has no meaningful unexpired composition-of-matter barrier in the U.S. The original Ativan product was approved decades ago, and multiple manufacturers sell generic tablets, concentrates and injections. The current commercial landscape is therefore driven more by regulatory execution, manufacturing reliability and product differentiation than by basic molecule patents.[4]
Orange Book status
The FDA Orange Book remains the controlling source for listed patents and exclusivity associated with approved U.S. reference products. Ativan’s legacy market protection has expired, and generic lorazepam products are established in the market. A current product-specific Orange Book review is required before filing because listed patents, pediatric exclusivity, discontinuation status and reference-product designations can change over time.[4]
The relevant intellectual-property categories are:
| IP category |
Lorazepam opportunity |
| Composition of matter |
No practical remaining U.S. barrier |
| Basic tablet formulation |
Weak, with many generic precedents |
| Alcohol-free oral solution |
Potential formulation patent opportunity |
| Cyclodextrin or nanosuspension system |
Potential composition-of-matter or formulation claims |
| ODT or buccal delivery |
Potential formulation and method-of-use claims |
| Dosing device and packaging |
Potential device, design and combination-product claims |
| Manufacturing process |
Possible trade-secret and process patent protection |
| Method of use |
Narrow opportunities because core anxiolytic and sedative uses are established |
A new formulation would generally need claims directed to a specific excipient ratio, physical form, stability profile, delivery system or pharmacokinetic result. Broad claims covering “lorazepam with a pharmaceutically acceptable excipient” would face substantial validity and prior-art risk.
When does lorazepam lose exclusivity?
Lorazepam already has lost its primary U.S. exclusivity. Generic competition is established, and no biosimilar pathway applies because lorazepam is a small-molecule drug, not a biologic.
| Milestone |
Commercial implication |
| Original Ativan approval |
Established the reference product |
| Legacy patent expiry |
Opened the market to ANDA applicants |
| Generic tablet approvals |
Removed most differentiation from conventional tablets |
| Generic concentrate and injection approvals |
Reduced the value of the original branded presentation |
| New differentiated formulation |
Could support a new 505(b)(2) or ANDA strategy, depending on changes |
A new dosage form may obtain its own patent term and regulatory exclusivity even though lorazepam itself is old. A 505(b)(2) application may be appropriate where the sponsor changes the route, formulation, strength, delivery system or excipient profile and relies partly on FDA findings for an approved lorazepam product.[5]
What Paragraph IV challenges and litigation affect lorazepam?
Paragraph IV litigation is not the primary commercial issue for ordinary lorazepam tablets because the foundational patents have expired and generic products are already marketed. A Paragraph IV strategy becomes relevant if a sponsor lists new formulation patents for an improved oral liquid, ODT, buccal product or injectable system.
The litigation risk would center on:
- Whether the new claims are genuinely distinct from prior art.
- Whether an ANDA applicant can design around the excipient ratios.
- Whether the listed patent claims a clinically meaningful formulation feature.
- Whether the patent is eligible for Orange Book listing.
- Whether a 30-month stay is available under the Hatch-Waxman framework.[4,6]
A formulation sponsor should expect limited value from weak, broad excipient claims. Narrow claims tied to reduced precipitation, improved stability, defined dissolution, lower solvent exposure or a specific delivery-device interface are more defensible.
No biosimilar litigation pathway applies. Lorazepam competition is through ANDAs, 505(b)(2) applications, authorized generics and state-level controlled-substance distribution channels.
How strong is the lorazepam patent estate?
The legacy lorazepam patent estate is weak for ordinary products and potentially moderate for engineered formulations.
| Asset |
Patent strength |
Reason |
| Standard immediate-release tablet |
Low |
Mature technology and extensive prior art |
| Conventional oral concentrate |
Low |
Established solvent systems and generic precedents |
| Conventional injection |
Low |
Longstanding parenteral formulation technology |
| Alcohol-free solution |
Moderate |
Potential formulation and tolerability differentiation |
| ODT |
Moderate |
Claims may cover disintegration, taste masking and stability |
| Buccal or sublingual film |
Moderate to high if clinically differentiated |
Route and delivery claims can create a distinct product |
| Low-PG or PG-free injection |
Moderate |
Formulation and safety claims may be available |
| Device-enabled dosing system |
Moderate |
Device and combination-product claims may provide layered protection |
| Manufacturing process |
Moderate |
Stronger as trade secret than as a broad patent in some cases |
The strongest protection would combine formulation claims, manufacturing-process claims, device claims and regulatory exclusivity. A single excipient patent would not provide a durable commercial moat against a low-cost generic market.
What FDA regulatory pathways apply to new lorazepam formulations?
An ANDA is most suitable for a product that matches the reference listed drug in dosage form, route, strength and conditions of use and can satisfy bioequivalence requirements.
A 505(b)(2) application is more suitable for:
- A new oral solution with a materially different excipient system.
- A buccal, sublingual or intranasal product.
- A novel injectable formulation.
- A product with a new dosing device.
- A product with a different pharmacokinetic profile or administration method.
FDA will focus on bioequivalence, dose proportionality, food effect where relevant, excipient safety, impurity control, container closure, microbiological quality and abuse-related risks. For injectable products, visible and subvisible particles, sterility, endotoxins, extractables and leachables are critical.
Lorazepam is a Schedule IV controlled substance under the federal Controlled Substances Act. Manufacturing, distribution, inventory controls, recordkeeping and security obligations increase operating complexity and favor suppliers with established controlled-substance systems.[7]
What commercial opportunities exist for lorazepam manufacturers?
Hospital and institutional products
Hospitals may value:
- Preservative-free or lower-solvent injection.
- Ready-to-use syringes.
- Unit-dose vials with reduced preparation steps.
- Stable products with a longer in-use window.
- Reliable supply during generic shortages.
- Barcoded packaging compatible with medication administration systems.
The injectable opportunity is technically attractive but demanding. Reducing propylene glycol or polyethylene glycol can improve the product profile, but the new solvent system must preserve solubility, stability and injection tolerability.
Pediatric and geriatric products
Pediatric demand supports alcohol-free, low-volume oral liquids with accurate dosing. Geriatric demand supports easy-swallow tablets, ODTs and excipient-minimized products. Both segments benefit from taste masking and calibrated administration devices.
The formulation must avoid creating new risks. Sweeteners, polyols and surfactants can affect gastrointestinal tolerability. Benzyl alcohol and high propylene glycol exposure are particular concerns in vulnerable populations, depending on dose and treatment duration.
Orally disintegrating and buccal products
An ODT could improve administration for patients who cannot swallow tablets, but it would compete with the low price of standard tablets. A buccal or sublingual product could offer faster onset or reduced dependence on gastrointestinal absorption, but those claims require clinical support.
The key development questions are:
- Does the product produce a clinically useful onset advantage?
- Is the dose fully delivered without swallowing?
- Can taste be controlled at a potent but bitter drug load?
- Does the dosage form remain stable under humidity stress?
- Can the product avoid accidental transfer or pediatric access?
Geographic opportunities
U.S. products face controlled-substance and FDA requirements. European products face national authorization, mutual-recognition or decentralized procedures, along with excipient labeling and pharmacovigilance requirements. Emerging markets may offer demand for oral liquids and injectables but can impose local registration, serialization and controlled-substance import requirements.
A global excipient strategy should avoid unnecessary use of alcohol, propylene glycol and colorants where regional labeling or pediatric standards differ. A common core formulation with market-specific packaging may reduce complexity.
What generic launch risks exist for lorazepam?
Generic launch risk is relatively low for ordinary tablets because multiple suppliers and established manufacturing processes already exist. Risk is higher for differentiated products.
| Risk |
Impact |
| Low price of conventional generics |
Limits premium pricing |
| Controlled-substance compliance |
Raises operational and audit costs |
| Small dose and potent active ingredient |
Increases content-uniformity risk |
| Poor lorazepam solubility |
Complicates liquid development |
| Solvent toxicity or tolerability |
Can undermine pediatric and geriatric positioning |
| Taste masking failure |
Reduces adherence |
| Precipitation after dilution |
Creates administration risk |
| Short shelf life |
Increases inventory write-offs |
| Limited clinical differentiation |
Weakens 505(b)(2) value |
| Hospital contracting pressure |
Compresses injectable margins |
Revenue exposure is concentrated in high-volume generic tablets and institutional injectable supply. Public company filings generally do not isolate lorazepam revenue, so product-level sales estimates should not be used without subscription market data or company-specific disclosures.
How does lorazepam compare with competing benzodiazepines?
Lorazepam competes with diazepam, midazolam, alprazolam and clonazepam. Its commercial position differs by route and use.
| Drug |
Key formulation advantage |
Competitive implication |
| Lorazepam |
Established tablet, concentrate and injection portfolio |
Broad route coverage and mature generic demand |
| Diazepam |
Multiple oral, rectal and injectable presentations |
Strong competition in emergency and seizure-related use |
| Midazolam |
Rapid parenteral and intranasal options |
Stronger acute-care and procedural positioning |
| Alprazolam |
High-volume oral anxiety market |
Greater tablet competition |
| Clonazepam |
Long-acting oral treatment profile |
Different duration and use pattern |
Lorazepam’s best formulation opportunity is a safer and more convenient presentation, not another undifferentiated immediate-release tablet.
Key Takeaways
- Lorazepam’s core U.S. molecule and conventional dosage forms are long genericized.
- Standard tablets offer limited patent and pricing upside.
- The strongest excipient opportunities are alcohol-free oral liquids, reduced-propylene-glycol injections, ODTs and buccal systems.
- Cyclodextrins, taste-masking systems and device-enabled dosing may support 505(b)(2) products.
- A new formulation needs measurable benefits in stability, tolerability, onset, dosing accuracy or administration convenience.
- Lorazepam is a Schedule IV controlled substance, creating manufacturing, distribution and inventory obligations.
- No biosimilar pathway applies.
- Formulation patents are more commercially relevant than legacy molecule patents.
- Hospital-ready injectable products and pediatric oral liquids offer the clearest commercial niches.
- Ordinary generic tablets face low launch risk but limited margin potential.
FAQs
Can propylene glycol be removed from lorazepam oral liquid?
Yes, but removal requires a replacement solubilization system that maintains concentration, stability, taste and dose uniformity. Cyclodextrin complexes, surfactants and nanosized dispersions are possible approaches.
Is lorazepam suitable for an orally disintegrating tablet?
Yes. Lorazepam’s low dose is compatible with ODT development, although taste masking, content uniformity, humidity protection and dose delivery must be demonstrated.
Can a new lorazepam formulation receive three-year FDA exclusivity?
A qualifying 505(b)(2) application may receive three-year exclusivity for new clinical investigations essential to approval. The exclusivity would apply to the approved change, not to lorazepam generally.[5]
Are lorazepam excipients subject to controlled-substance regulation?
The excipients are not generally controlled as Schedule IV substances, but the finished lorazepam product, manufacturing records, inventory and distribution activities are subject to controlled-substance requirements.
What is the most commercially attractive lorazepam formulation?
An alcohol-free, low-volume oral liquid with accurate dosing and broad pediatric and geriatric usability has the clearest differentiated opportunity. A low-solvent ready-to-use injection is the stronger hospital-focused opportunity.
References
-
U.S. Food and Drug Administration. (2024). DailyMed: Lorazepam tablet labeling. National Library of Medicine. https://dailymed.nlm.nih.gov/
-
U.S. Food and Drug Administration. (2024). DailyMed: Lorazepam oral concentrate labeling. National Library of Medicine. https://dailymed.nlm.nih.gov/
-
U.S. Food and Drug Administration. (2024). DailyMed: Lorazepam injection labeling. National Library of Medicine. https://dailymed.nlm.nih.gov/
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th edition. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book
-
U.S. Food and Drug Administration. (2019). Applications covered by section 505(b)(2). https://www.fda.gov/regulatory-information
-
U.S. Food and Drug Administration. (2024). Hatch-Waxman amendments and abbreviated new drug applications. https://www.fda.gov/drugs
-
U.S. Drug Enforcement Administration. (2024). Drug scheduling. https://www.dea.gov/drug-information/drug-scheduling
